A century after the last major TB vaccine breakthrough, Gates and Wellcome commit $550M for PhIII test of GSK shot

Ryan Cross

Senior Science Correspondent

Two nonprofit organizations are teaming up for a giant study of an experimental vaccine designed to protect against the world’s deadliest infectious disease.

The Bill …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A century after the last major TB vaccine breakthrough, Gates and Wellcome commit $550M for PhIII test of GSK shot

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

A cen­tu­ry af­ter the last ma­jor TB vac­cine break­through, Gates and Well­come com­mit $550M for PhI­II test of GSK shot

Senior Science Correspondent

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

A century after the last major TB vaccine breakthrough, Gates and Wellcome commit $550M for PhIII test of GSK shot